Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Net Income towards Common Stockholders: 2015-2025

Historic Net Income towards Common Stockholders for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$25.1 million.

  • Editas Medicine's Net Income towards Common Stockholders rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 56.38% down from last year.
  • Editas Medicine's Net Income towards Common Stockholders amounted to -$25.1 million in Q3 2025, which was up 51.21% from -$51.5 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Net Income towards Common Stockholders ranged from a high of -$18.9 million in Q4 2023 and a low of -$75.7 million during Q1 2025.
  • For the 3-year period, Editas Medicine's Net Income towards Common Stockholders averaged around -$49.2 million, with its median value being -$47.5 million (2023).
  • As far as peak fluctuations go, Editas Medicine's Net Income towards Common Stockholders plummeted by 600.08% in 2021, and later surged by 68.95% in 2023.
  • Editas Medicine's Net Income towards Common Stockholders (Quarterly) stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then surged by 68.95% to -$18.9 million in 2023, then crashed by 140.68% to -$45.4 million in 2024, then spiked by 59.58% to -$25.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$25.1 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$75.7 million in Q1 2025.